von Schlippe M, Rustin G J
Department of Medical Oncology, Mount Vernon Centre for Cancer Treatment, Northwood, Middlesex, UK.
Forum (Genova). 2000 Oct-Dec;10(4):383-92.
Many circulating tumour markers are in clinical or experimental use for the management of ovarian tumours. The only marker to have an established role in the diagnosis, monitoring treatment, and detection of relapse of epithelial ovarian cancer (OC) is cancer antigen-125 (CA-125). The place of markers in predicting prognosis, in follow-up, and in screening for OC, is less well defined. This review concentrates on epithelial cancer of the ovary, and on CA-125, the most commonly-used OC marker. Other markers in epithelial OC are also discussed, as well as markers used in the management of germ cell tumours of the ovary, mixed Mullerian tumours, and stromal ovarian tumours.
许多循环肿瘤标志物在卵巢肿瘤的管理中处于临床应用或实验阶段。在诊断、监测治疗以及检测上皮性卵巢癌（OC）复发方面具有确定作用的唯一标志物是癌抗原125（CA-125）。标志物在预测OC预后、随访以及筛查中的作用尚不太明确。本综述着重于卵巢上皮癌以及最常用的OC标志物CA-125。还讨论了上皮性OC中的其他标志物，以及用于卵巢生殖细胞肿瘤、混合性苗勒管肿瘤和卵巢间质肿瘤管理的标志物。
